Inhibiting TNF-? activity by adalimumab significantly improves signs and symptoms, physical function, and quality of life for people suffering with RA.1,6
Adalimumab, in combination with MTX, or as monotherapy, is recommended by NICE for treating adults with severe RA, who haven’t responded to disease modifying antirheumatic drugs (DMARDs).
Adalimumab in combination with methotrexate (MTX) was 5 times more effective, on average at slowing the progression of joint damage than MTX alone after 2 years.
Taking adalimumab with MTX had a 20% improvement in signs and symptoms of RA, after 6 months.
Adalimumab is a recombinant human immunoglobulin (IgG_1) anti-tumour necrosis factor (TNF) monoclonal antibody. It is a TNF antagonist that works as an anti-inflammatory medication to treat autoimmune diseases. It inhibits the progression of joint damage and reduces signs and symptoms of rheumatoid arthritis (RA).